Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025

DOVER, Del., Nov. 6, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases, today announced the upcoming presentation of preclinical data for its first-in-class, wild-type–sparing...